Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Shareholders of Mylan would get around 40% of the newly formed business and Pfizer shareholders would get the remaining 60%, according to Reuters.
Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.
Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
Bausch Health gain after key reduction in debt and rollout of new psoriasis treatment lotion.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.